GlaxoSmithKline Pharmaceuticals has reported results for fourth quarter ended December 31, 2012.
The company has reported 1.29% rise in its net profit at Rs 138.51 crore for the quarter as compared to Rs 136.74 crore for the same quarter in the previous year. Total income of the company has increased by 13.74% at Rs 704.34 crore for quarter under review as compared to Rs 619.25 crore for the quarter ended December 31, 2011.
For the entire 2012 fiscal, the company’s net profit surged 34.06% to Rs 577.26 crore from Rs 430.60 crore in the previous fiscal. The total income from operations went up by 11.37% to Rs 2823.78 crore from Rs 2535.50 crore in last year.
For the entire fiscal, the company’s consolidated net profit rose 31.10% to Rs 561.88 crore from Rs 428.58 crore in the previous fiscal. The total consolidated income of the company went up by 10.36% to Rs 2824.85 crore from Rs 2559.67 crore in last year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: